Search research articles
Contact Us
Filters
Showing results (21-30 of 44) with videos related to
Page
of 5
Sort By:
JACC. Heart Failure
|
December 10, 2025
Framework for Analytical Validation of DHT-Based Actigraphy and Signal Measures in HF Trials: The VALIDATE-HF Program
Orhun Kose, Aymen Sahal, Guang K Zhang, et al.
The Lancet. Haematology
|
December 22, 2015
Cyclophosphamide conditioning in patients with severe aplastic anaemia given unrelated marrow transplantation: a phase 1-2 dose de-escalation study
Paolo Anderlini, Juan Wu, Iris Gersten, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 9, 2021
Biologic Assignment Trial of Reduced-Intensity Hematopoietic Cell Transplantation Based on Donor Availability in Patients 50-75 Years of Age With Advanced Myelodysplastic Syndrome
Ryotaro Nakamura, Wael Saber, Michael J Martens, et al.
The Journal of Infectious Diseases
|
March 4, 2025
Viral and Immune Factors Associated With COVID-19 Outcome in the C3PO Trial of Convalescent Plasma
Clara Di Germanio, Erika G Marques de Menezes, Robert Clevenger, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
April 6, 2017
Myeloablative Versus Reduced-Intensity Hematopoietic Cell Transplantation for Acute Myeloid Leukemia and Myelodysplastic Syndromes
Bart L Scott, Marcelo C Pasquini, Brent R Logan, et al.
The Lancet. Haematology
|
July 30, 2022
Haploidentical bone marrow transplantation in patients with relapsed or refractory severe aplastic anaemia in the USA (BMT CTN 1502): a multicentre, single-arm, phase 2 trial
Amy E DeZern, Mary Eapen, Juan Wu, et al.
JAMA
|
March 21, 2023
Heterogeneous Treatment Effects of Therapeutic-Dose Heparin in Patients Hospitalized for COVID-19
Ewan C Goligher, Patrick R Lawler, Thomas P Jensen, et al.
Transplantation and Cellular Therapy
|
March 29, 2021
Myeloablative versus Reduced-Intensity Conditioning for Hematopoietic Cell Transplantation in Acute Myelogenous Leukemia and Myelodysplastic Syndromes-Long-Term Follow-Up of the BMT CTN 0901 Clinical Trial
Bart L Scott, Marcelo C Pasquini, Mingwei Fei, et al.
Bone Marrow Transplantation
|
February 27, 2025
Correction: Anti-CD3/CD7 immunoconjugate (T-Guard) for severe, steroid-refractory GVHD: final report of BMT CTN 2002
Gabrielle Meyers, Mehdi Hamadani, Michael Martens, et al.
Bone Marrow Transplantation
|
September 25, 2023
Anti-CD3/CD7 immunoconjugate (T-Guard) for severe, steroid-refractory GVHD: final report of BMT CTN 2002
Gabrielle Meyers, Mehdi Hamadani, Michael Martens, et al.
Page
of 5
Search research articles
Search
Showing results (21-30 of 44) with videos related to
Sort By:
Page
of 5
JACC. Heart Failure
|
December 10, 2025
Framework for Analytical Validation of DHT-Based Actigraphy and Signal Measures in HF Trials: The VALIDATE-HF Program
Orhun Kose, Aymen Sahal, Guang K Zhang, et al.
The Lancet. Haematology
|
December 22, 2015
Cyclophosphamide conditioning in patients with severe aplastic anaemia given unrelated marrow transplantation: a phase 1-2 dose de-escalation study
Paolo Anderlini, Juan Wu, Iris Gersten, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 9, 2021
Biologic Assignment Trial of Reduced-Intensity Hematopoietic Cell Transplantation Based on Donor Availability in Patients 50-75 Years of Age With Advanced Myelodysplastic Syndrome
Ryotaro Nakamura, Wael Saber, Michael J Martens, et al.
The Journal of Infectious Diseases
|
March 4, 2025
Viral and Immune Factors Associated With COVID-19 Outcome in the C3PO Trial of Convalescent Plasma
Clara Di Germanio, Erika G Marques de Menezes, Robert Clevenger, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
April 6, 2017
Myeloablative Versus Reduced-Intensity Hematopoietic Cell Transplantation for Acute Myeloid Leukemia and Myelodysplastic Syndromes
Bart L Scott, Marcelo C Pasquini, Brent R Logan, et al.
The Lancet. Haematology
|
July 30, 2022
Haploidentical bone marrow transplantation in patients with relapsed or refractory severe aplastic anaemia in the USA (BMT CTN 1502): a multicentre, single-arm, phase 2 trial
Amy E DeZern, Mary Eapen, Juan Wu, et al.
JAMA
|
March 21, 2023
Heterogeneous Treatment Effects of Therapeutic-Dose Heparin in Patients Hospitalized for COVID-19
Ewan C Goligher, Patrick R Lawler, Thomas P Jensen, et al.
Transplantation and Cellular Therapy
|
March 29, 2021
Myeloablative versus Reduced-Intensity Conditioning for Hematopoietic Cell Transplantation in Acute Myelogenous Leukemia and Myelodysplastic Syndromes-Long-Term Follow-Up of the BMT CTN 0901 Clinical Trial
Bart L Scott, Marcelo C Pasquini, Mingwei Fei, et al.
Bone Marrow Transplantation
|
February 27, 2025
Correction: Anti-CD3/CD7 immunoconjugate (T-Guard) for severe, steroid-refractory GVHD: final report of BMT CTN 2002
Gabrielle Meyers, Mehdi Hamadani, Michael Martens, et al.
Bone Marrow Transplantation
|
September 25, 2023
Anti-CD3/CD7 immunoconjugate (T-Guard) for severe, steroid-refractory GVHD: final report of BMT CTN 2002
Gabrielle Meyers, Mehdi Hamadani, Michael Martens, et al.
Page
of 5